[8-K] SS Innovations International, Inc. Reports Material Event

Rhea-AI Filing Summary

SS Innovations International (SSII) announced management participation in two investor conferences. The company will join the UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 11, 2025, and the Stifel 2025 Healthcare Conference in New York, NY on November 12, 2025. The Stifel event includes a group presentation at 4:40 p.m. Eastern Time.

A live webcast and replay of the Stifel presentation will be available on the company’s website at https://ssinnovations.com/investor-overview/. The disclosure is provided under Item 7.01 (Regulation FD) and is deemed “furnished,” not “filed.”

false 0001676163 0001676163 2025-10-21 2025-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 21, 2025

SS INNOVATIONS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Florida		001-42615		47-3478854
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

05, 3rd Floor, iLabs Info Technology Centre Udyog Vihar, Phase III, Gurugram, Haryana, India		122016
Address of Principal Executive Office (Street and Number)		(Zip Code)

Registrant’s telephone number, including area code: +91 73375 53469

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
Common Stock		SSII		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.

Item 7.01. Regulation FD Disclosure.

On October 21, 2025, the Company issued a press release announcing that Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer, and Dr. Vishwa Srivastava, Chief Executive Officer – Asia Pacific, are scheduled to participate in the following upcoming investor conferences:

UBS Global Healthcare Conference

Palm Beach Gardens, FL

Tuesday, November 11, 2025

Management will be available for one-on-one and small group meetings throughout the day.

Stifel 2025 Healthcare Conference

New York, NY

Wednesday, November 12, 2025

Group presentation: 4:40 p.m. Eastern Time

Management will be available for one-on-one and small group meetings throughout the day.

A live webcast and replay of the Stifel group presentation will be accessible on the Company’s website at https://ssinnovations.com/investor-overview/.

A copy of the press release is included with this Report as Exhibit 99.1.

The information set forth in this Item 7.01, in the press release included with this Report as Exhibit 99.1, and in the Stifel group presentation which will be accessible on the Company’s website through the link set forth above, are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01, in the press release included with this Report as Exhibit 99.1, and in the Stifel group presentation which will be accessible on the Company’s website through the link set forth above, including without limitation, information accessed through the link set forth above, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Forward-Looking Statements

This Report may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SSi’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in its forward-looking statements are set forth in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to SSi’s operations, results of operations, growth strategy and liquidity.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1*		Press Release dated October 21,  2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished but not filed.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 21, 2025	SS INNOVATIONS INTERNATIONAL, INC.
	By:	/s/ Sudhir Srivastava
		Sudhir Srivastava, M.D.
		Chairman and Chief Executive Officer

2

FAQ

What did SSII announce in its 8-K?

The company disclosed participation in the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025.

When and where is the UBS Global Healthcare Conference for SSII?

It is scheduled for November 11, 2025, in Palm Beach Gardens, Florida.

When and where is the Stifel 2025 Healthcare Conference for SSII?

It is scheduled for November 12, 2025, in New York, New York, with a group presentation at 4:40 p.m. ET.

Will SSII provide a webcast of its presentation?

Yes. A live webcast and replay of the Stifel group presentation will be available at https://ssinnovations.com/investor-overview/.

How is this information treated under SEC rules?

It is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Exchange Act.

Who from SSII is participating?

Dr. Sudhir Srivastava (Chairman and CEO) and Dr. Vishwa Srivastava (CEO – Asia Pacific) are scheduled to participate.